Investigational drug · Phase 2
Monoclonal antibody
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cancer, HLA-A*02:01-positive, Refractory Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
15,722
Any phase or sponsor naming "Monoclonal antibody"
First trial start
2023
Aug 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Monoclonal antibody", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer
- HLA-A*02:01-positive
- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Monoclonal antibody" as an intervention, largest first.
- Saphnelo Use in Females of Child-bearing PotentialNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07431775 · 26,000,000 participants (planned) · Start Oct 1, 2026 · Primary completion Mar 31, 2032
Drug: Anifrolumab · For: Systemic Lupus Erythematosus
- Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)Status unknown
The First Affiliated Hospital of Xinxiang Medical CollegeAcademic, hospital or other
NCT06409481 · 800,000 participants (planned) · Start Jun 1, 2024 · Primary completion Jun 30, 2024
Drug: Antineoplastic Agents · For: Cardiovascular Diseases; Cardiac Diseases; Vascular Diseases and 1 more
AmgenAmgen (AMGN)
NCT02520362 · 517,991 participants · Start May 31, 2010 · Primary completion Jul 21, 2023
Drug: denosumab; bisphosphonate · For: Osteoporosis
National Cheng-Kung University HospitalAcademic, hospital or other
NCT05366621 · 216,155 participants · Start Nov 1, 2020 · Primary completion Sep 30, 2021
Drug: Anti-osteoporosis medications · For: Osteoporosis; Osteoporosis Fracture; Drug Therapy and 2 more
Sites: Tainan, Taiwan
Brigham and Women's HospitalAcademic, hospital or other
NCT04772248 · 105,711 participants · Start Feb 22, 2021 · Primary completion Dec 30, 2021
Drug: Tofacitinib; TNF Inhibitor · For: Rheumatoid Arthritis
Sites: Boston, Massachusetts
- Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer EndpointsCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT04798287 · 105,711 participants · Start Mar 10, 2021 · Primary completion Dec 31, 2021
Drug: Tofacitinib; TNF Inhibitor · For: Rheumatoid Arthritis
Sites: Boston, Massachusetts
BiogenBiogen (BIIB)
NCT03399981 · 80,327 participants · Start Jun 1, 2017 · Primary completion Dec 31, 2023
Drug: Tysabri · For: Progressive Multifocal Leukoencephalopathy
Sites: Cambridge, Massachusetts
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
BiogenBiogen (BIIB)
NCT01070836 · 35,895 participants · Start Mar 2010 · Primary completion Nov 2015
Drug: natalizumab · For: Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Tucaloosa, Alabama · 478 sites in all
Karolinska InstitutetAcademic, hospital or other
NCT03390608 · 35,002 participants · Start Jan 1, 1977 · Primary completion Dec 31, 2014
Drug: Endocrine therapy; Herceptin and 1 more · For: Breast Cancer
Sites: Solna, Sweden
Newest research
PubMed records naming it or its code names, newest first.
- From laboratory quantification to rapid on-site testing: Screening of high-affinity monoclonal antibody pairs targeting the RSV F protein and analytical evaluation across multiple assay platforms.
Peng S, Liu Q, Duan C, et al. · Talanta 2027
- Bubble-cell native fluorescence imaging for high-sensitivity label-free protein quantification.
Xu H, Nguyen U, Yang T · Talanta 2027
- Development and clinical application of a sensitive enzyme-linked immunosorbent assay for neutrophil elastase as a serum biomarker of myocardial infarction.
Wang Y, Zhou J, Shu Z, et al. · Clin Chim Acta 2027
- Melatonin ameliorates anxiety-like behavior and intestinal barrier dysfunction induced by high-fat diet in BTBR mice.
Cai Y, Yang Q, Song J, et al. · Neuropharmacology 2027
- A one-step functionalized 3D-printed electrochemical biosensor for serotype-selective detection of dengue NS1.
D'Amato DL, Caldas NM, de Faria LV, et al. · Biosens Bioelectron 2027
- Super-antifouling electrochemical biosensor based on a biomimetic gemini zwitterionic interface for sensitive detection of therapeutic antibodies.
Zhao Z, Yu W, Li H, et al. · Bioelectrochemistry 2027
Also in development for Cancer
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- EmactuzumabPhase 32 trials
Roche (Genentech) · Cancer, TGCT
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- ADCAntibody-drug conjugate, ADCE-D01Phase 23 trials
MBrace Therapeutics · Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.